NSE/GLAXO

GLAXOGLAXO

NSE Equity · NSE

₹2,453.9+1.41%

52-wk low52-WEEK RANGE52-wk high

₹2,259.5+8.6% from low ·-29.2% from high₹3,466.2

Price chart · 1M–10Y · daily-close

NSE bhavcopy + 10Y historical

GLAXO-8.28% · 1Y

Range high ₹3,515.7Range low ₹2,217.6Latest ₹2,453.9252 bars · daily-close · NSE bhavcopy + 10Y history

NSE EquityDrug Manufacturers - GeneralMidcapLow Risk

Stock scorecard

Auto-computed from latest ratios + sector context · not a buy/sell signal

Composite38/100

Performance

Low

Hasn't fared well — amongst the weak performers.

· 52w return -12.8% — underperformer
· Below 200-DMA (-6.7%) — downtrend

Valuation

High

Looks expensive vs the sector.

· P/E 40.4 — 63% above sector median 24.8
· P/B 24.17 above sector median

Growth

Medium

Steady but not standout growth.

· Revenue YoY +8.6%
· Profit YoY +57.2% — strong earnings growth

Profitability

High

Showing good signs of profitability & efficiency.

· ROE 59.9% — high-quality compounder
· Net margin 24.7% — strong pricing power

DVM composite · Durability · Valuation · Momentum

Trendlyne-style 3-axis composite · all drivers shown below · not a buy/sell signal

CompositeC(56/100)

Durability

A+

100/100

Financially resilient — strong quality + solvency profile.

Show 2 drivers

Debt/Equity0.02 (100pt)
ROE59.9% (100pt)

Valuation

21/100

Richly valued on most axes; limited margin of safety.

Show 4 drivers

P/E vs sector (40.4 / 24.8)163% (27pt)
P/B24.17 (0pt)
Dividend yield1.71% (43pt)
EV/EBITDA31.3 (17pt)

Momentum

46/100

Momentum is muted; trend is unclear or rolling over.

Show 5 drivers

52w change-12.8% (29pt)
DMA-trend alignmentdown (25pt)
RSI (14)57.5 (97pt)
Price vs 200-DMA-7.6% (45pt)
MACD regimebullish (75pt)

Valuation positioning

Current ratio vs sector peer distribution

P/E (TTM)40.36

FAIR

CheapestP/E 40.4 near sector median.Most expensive

P/B24.17

OVERVALUED

CheapestP/B 24.17 at 89th %ile of sector.Most expensive

EV/EBITDA31.31

OVERVALUED

Monthly seasonality

Avg monthly return over 10 years · historical — not a forecast

Best: May +3.67% · Worst: Jan -2.78%

Jan

-2.8%

20% win

Feb

+0.1%

30% win

Mar

-1.5%

30% win

Apr

+2.4%

60% win

May

+3.7%

50% win

Jun

+2.6%

Monthly return distribution

Distribution of 120 monthly returns

Mean

+0.55%

Median

-0.98%

Std dev

8.07%

Best

+25.5%

Worst

-21.6%

% positive

46%

SWOT analysis

Auto-derived from ratios + sector context + forensics · research only, not a recommendation

STRENGTHS · 4

High-quality compounder (ROE 59.9%)
Above 20% ROE consistently flags capital-efficient businesses
Lean balance sheet (D/E 0.02)
Low leverage means earnings are less sensitive to rate cycles
Strong net margin (24.7%)
High margin indicates pricing power + operating efficiency
Top quartile ROE in Other
Rank 10 of 1000 peers

WEAKNESSES · 1

Premium to sector on P/E (+63%)
P/E 40.4 vs Other median 24.8

OPPORTUNITIES · 1

23% upside to consensus target (₹2992)
4 analysts see fair value materially higher

THREATS · 1

Valuation compression risk
P/E 40.4 is 63% above sector — any growth miss gets punished

RETURNS · DAILY-CLOSE BASED

3Y+ shown as CAGR

+1.4%

+2.5%

+1.2%

+2.3%

-9.0%

-10.1%

+22.9%

+10.1%

10Y

+2.8%

Peer	Last close	1Y change	Mcap ₹Cr	P/E	P/B	ROE	D/E	Rev YoY
GLAXOTHIS GlaxoSmithKline Pharmaceuticals Limited	₹2,453.9	-12.8%	41,279	40.4	24.17	59.9%	0.02	+8.6%
ABCAPITAL Aditya Birla Capital Limited	₹340.4	+68.1%	89,888	25.8	2.79	10.8%	4.60	+17.6%
ABBOTINDIA Abbott India Limited	₹25,785	-16.6%	54,547	35.8	13.60	38.0%	0.04	+9.6%
360ONE 360 ONE WAM LIMITED	₹1,113.3	+16.7%	44,744	38.7	4.77	12.3%	1.47	+35.0%
3MINDIA 3M India Limited	₹31,410	+4.4%	35,158	92.9	21.83	23.5%	0.06	+6.1%
AADHARHFC Aadhar Housing Finance Limited	₹496.45	+3.5%	21,173	20.8	3.05	14.6%	2.55	—
ABDL Allied Blenders and Distillers Limited	₹573.8	+76.4%	16,176	60.4	10.70	17.7%	0.67	+5.8%
AAVAS Aavas Financiers Limited	₹1,347.9	-37.8%	10,612	17.1	2.26	13.3%	3.08	+13.3%
63MOONS 63 moons technologies limited	₹662.7	-9.8%	8,006	—	0.92	-0.2%	0.00	-6.3%

ASK AXEL

Dig deeper into GLAXO

Axel can fetch latest news, peer valuation, consensus estimates, insider activity, and concall commentary for GLAXO — all in one sourced reply.

Ask free in chat

Run these tools on GLAXO

Historical return →

"If I had bought GLAXO in year X"

Rolling returns →

Worst/best 1/3/5/7/10-yr windows

Buy-the-dip backtester →

Dip-buying vs SIP on GLAXO

Brokerage + charges →

All-in cost for trading GLAXO

Research tool · not investment advice.

Axel Markets is an information + analytics product. We are not a SEBI-registered Research Analyst (RA) or Investment Adviser (IA). Nothing on this page is a buy, sell, or hold recommendation. Past performance is not indicative of future returns. Verify all data against the authoritative source (NSE, BSE, AMFI, SEBI, company RHP / factsheet) before acting. Daily OHLCV sourced primarily from our NSE bhavcopy ingest (public sec_bhavdata_full CSV), with Stooq as a fallback for historical gaps. Split + bonus adjusted. Excludes dividends. Not a recommendation. Past performance does not predict future returns. For authoritative live quotes see NSE / BSE directly.

Date	Amount
2025-05-30	₹42.00
2024-11-07	₹12.00
2024-05-31	₹32.00
2023-06-30	₹32.00
2022-07-07	₹90.00
2021-07-19	₹30.00
2020-07-17	₹40.00
2019-07-11	₹20.00
2018-07-13	₹17.50
2017-07-14	₹15.00
2016-07-15	₹25.00

GLAXOGLAXO

Price chart · 1M–10Y · daily-close

Stock scorecard

DVM composite · Durability · Valuation · Momentum

Valuation positioning

Monthly seasonality

Monthly return distribution

SWOT analysis

Fundamentals

Peer comparison · Other

Ask Axel about GLAXO

Recent news

Dig deeper into GLAXO

Run these tools on GLAXO

Technical snapshot

Dividends + splits history

Stock scorecard

SWOT analysis

Recent news

DVM composite · Durability · Valuation · Momentum

Valuation positioning

Monthly seasonality

Monthly return distribution

Fundamentals

Pros and cons

Sector-relative context

Analyst consensus

Company + balance sheet snapshot

Peer comparison · Other